EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Population‐Based Modeling to Predict Human PK / PD of TAK ‐500, an Anti‐CCR2 Antibody–Drug Conjugate for First‐in‐Human Study in Cancer Patients

Anitha Saravanakumar iD, Rong Deng, Linlin Dong, Satyajeet Haridas, Cindy Q Xia, Vicky A Appleman, Adnan O Abu-Yousif, Konstantin Piatkov, Haiqing Wang

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70522 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Anitha Saravanakumar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Preclinical Candidate Optimization, Bristol Myers Squibb, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Receptors, CCR2, Neoplasms, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TAK‐500 is a novel immune cell–directed antibody–drug conjugate (iADC) composed of TAK‐202, an anti‐CCR2 monoclonal antibody, conjugated to the STING agonist dazostinag (TAK‐676), and is designed to stimulate antitumor immunity by reprogramming CCR2‐positive monocytes. To support clinical translation, we developed a population pharmacokinetic (PK)–receptor occupancy (RO) model that leveraged both preclinical and clinical data from the parental antibody. In cynomolgus monkeys, TAK‐500 displayed nonlinear, target‐mediated disposition with dose‐dependent CCR2 RO and monocyte redistribution. A 2‐compartment PK model confirmed that TAK‐500 total antibody and TAK‐202 exhibited comparable PK profiles in monkeys, suggesting translational concordance. In humans, TAK‐202 demonstrated nonlinear PK with greater‐than‐dose‐proportional exposure, which was not captured by allometric scaling from monkeys but provided a critical basis for model development. We established a population PK–RO model of TAK‐202 in humans and integrated it with cynomolgus TAK‐500 data to project human PK and RO across doses of 50–500 μg/kg. Simulations ( n = 1000) predicted dose‑dependent decreases in clearance, from 40 to 31 mL/h for total antibody and from 148 to 124 mL/h for conjugated payload (median values in a 70‑kg adult), respectively. Corresponding terminal half‐lives were estimated at 114–118 h for total antibody and 30–60 h for conjugated payload. These findings demonstrate the feasibility of predicting TAK‐500 PK and RO in humans by integrating preclinical and parental antibody clinical data, providing a quantitative framework for first‐in‐human dose selection of immune cell–directed ADCs. Trial Registration: Clinical trials: NCT04420884, NCT04879849

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesReceptors, CCR2NeoplasmsModels, BiologicalAntibodies, MonoclonalHumansAnimalsMacaca fascicularisFemaleMaleAdultMonocytesDose-Response Relationship, DrugMiddle Aged

Stichwörter der Autor:innen

ADCCCR2STING agonistTMDDpopulation‐based PKPD modeling

Substanzen

ImmunoconjugatesReceptors, CCR2CCR2 protein, humanAntibodies, Monoclonal

Autor:innen und Institutionen

  • Preclinical Candidate Optimization, Bristol Myers Squibb, Cambridge, Massachusetts, USA.
  • R&D Q-Pharm Consulting LLC, Pleasanton, California, USA.
  • Department of Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, USA.
  • ZS Associates, Boston, Massachusetts, USA.
  • Translational Sciences, City Therapeutics Inc., Cambridge, Massachusetts, USA.
  • Oncology Drug Discovery Unit, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, USA.

ORCID-Profile: Anitha Saravanakumar

Zitieren

APA

Saravanakumar, A., Deng, R., Dong, L., Haridas, S., Xia, C. Q., Appleman, V. A., Abu-Yousif, A. O., Piatkov, K., & Wang, H. (2026). Population‐Based Modeling to Predict Human PK / PD of TAK ‐500, an Anti‐CCR2 Antibody–Drug Conjugate for First‐in‐Human Study in Cancer Patients. Clinical and Translational Science. https://doi.org/10.1111/cts.70522

Vancouver

Saravanakumar A, Deng R, Dong L, Haridas S, Xia CQ, Appleman VA, et al. Population‐Based Modeling to Predict Human PK / PD of TAK ‐500, an Anti‐CCR2 Antibody–Drug Conjugate for First‐in‐Human Study in Cancer Patients. Clinical and Translational Science. 2026. doi:10.1111/cts.70522

BibTeX
@article{Saravanakumar2026,
  author = {Saravanakumar, Anitha and Deng, Rong and Dong, Linlin and Haridas, Satyajeet and Xia, Cindy Q and Appleman, Vicky A and Abu-Yousif, Adnan O and Piatkov, Konstantin and Wang, Haiqing},
  title = {Population‐Based Modeling to Predict Human PK / PD of TAK ‐500, an Anti‐CCR2 Antibody–Drug Conjugate for First‐in‐Human Study in Cancer Patients},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70522}
}
Kostenlos starten →